Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-04-26
2011-12-27
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S04400A, C514S002600, C424S130100, C530S387100, C536S024500
Reexamination Certificate
active
08084434
ABSTRACT:
The present invention relates to RUNX2 and RUNXdelta8, and their use in modulating conditions and diseases associated with angiogenesis and cell proliferation. For example, RUNX2delta8 can be utilized to inhibit tumor growth and to prevent or inhibit angiogenesis. The present invention also relates to antibodies which specifically recognize RUNX2delta8, and distinguish it from RUNX2.
REFERENCES:
Jadwiga et al. Med Sci Monit vol. 10(4):RA89-98, 2004.
International Search Report of Jan. 23, 2008 for International Application No. PCT/US05/14137 filed on Apr. 26, 2005.
Sun et al., “Regulation of TGFbetal-Medicated Growth Inhibition and Apoptosis by RUNX2 Isoforms in Endothelial Cells,” Oncogene, vol. 23, Apr. 26, 2004, pp. 4722-4734.
Passanti Antonino
Sun Lixin
Evans Judith
Evans & Molinelli PLLC
McGarry Sean
University of Maryland Baltimore
LandOfFree
Runx2 isoforms in angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Runx2 isoforms in angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Runx2 isoforms in angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4316044